These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31092562)

  • 21. Telmisartan generates ROS-dependent upregulation of death receptor 5 to sensitize TRAIL in lung cancer via inhibition of autophagy flux.
    Rasheduzzaman M; Moon JH; Lee JH; Nazim UM; Park SY
    Int J Biochem Cell Biol; 2018 Sep; 102():20-30. PubMed ID: 29929000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fused hydrophobic elastin-like-peptides (ELP) enhance biological activity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Huang K; Duan N; Zou W; Zhang C; Lai Y; Shen P; Hua Z
    Protein Pept Lett; 2015; 22(11):1000-6. PubMed ID: 26299999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer.
    Zhang SF; Wang XY; Fu ZQ; Peng QH; Zhang JY; Ye F; Fu YF; Zhou CY; Lu WG; Cheng XD; Xie X
    Autophagy; 2015; 11(2):225-38. PubMed ID: 25607466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression.
    Stolfi C; Caruso R; Franzè E; Rizzo A; Rotondi A; Monteleone I; Fantini MC; Pallone F; Monteleone G
    Mol Cancer Ther; 2011 Oct; 10(10):1969-81. PubMed ID: 21817114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of autophagy flux by metformin downregulates cellular FLICE-like inhibitory protein and enhances TRAIL- induced apoptosis.
    Nazim UM; Moon JH; Lee JH; Lee YJ; Seol JW; Eo SK; Lee JH; Park SY
    Oncotarget; 2016 Apr; 7(17):23468-81. PubMed ID: 26992204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clitocine potentiates TRAIL-mediated apoptosis in human colon cancer cells by promoting Mcl-1 degradation.
    Sun JG; Ruan F; Zeng XL; Xiang J; Li X; Wu P; Fung KP; Liu FY
    Apoptosis; 2016 Oct; 21(10):1144-57. PubMed ID: 27421828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ULK1 phosphorylates Ser30 of BECN1 in association with ATG14 to stimulate autophagy induction.
    Park JM; Seo M; Jung CH; Grunwald D; Stone M; Otto NM; Toso E; Ahn Y; Kyba M; Griffin TJ; Higgins L; Kim DH
    Autophagy; 2018; 14(4):584-597. PubMed ID: 29313410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP.
    Rokhlin OW; Guseva NV; Tagiyev AF; Glover RA; Cohen MB
    Prostate; 2002 Jun; 52(1):1-11. PubMed ID: 11992615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autophagy as a mechanism of Apo2L/TRAIL resistance.
    Sharma A; Almasan A
    Cancer Biol Ther; 2018; 19(9):755-762. PubMed ID: 30067424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gefitinib enhances human colon cancer cells to TRAIL-induced apoptosis of via autophagy- and JNK-mediated death receptors upregulation.
    Chen L; Meng Y; Guo X; Sheng X; Tai G; Zhang F; Cheng H; Zhou Y
    Apoptosis; 2016 Nov; 21(11):1291-1301. PubMed ID: 27629794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line.
    Zhang L; Zhu H; Teraishi F; Davis JJ; Guo W; Fan Z; Fang B
    Neoplasia; 2005 Jun; 7(6):594-602. PubMed ID: 16036110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Niacin alleviates TRAIL-mediated colon cancer cell death via autophagy flux activation.
    Kim SW; Lee JH; Moon JH; Nazim UM; Lee YJ; Seol JW; Hur J; Eo SK; Lee JH; Park SY
    Oncotarget; 2016 Jan; 7(4):4356-68. PubMed ID: 26517672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wogonin enhances antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo through ROS-mediated downregulation of cFLIPL and IAP proteins.
    Yang L; Wang Q; Li D; Zhou Y; Zheng X; Sun H; Yan J; Zhang L; Lin Y; Wang X
    Apoptosis; 2013 May; 18(5):618-26. PubMed ID: 23371323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GA binding protein augments autophagy via transcriptional activation of BECN1-PIK3C3 complex genes.
    Zhu W; Swaminathan G; Plowey ED
    Autophagy; 2014 Sep; 10(9):1622-36. PubMed ID: 25046113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancement of tumor-TRAIL susceptibility by modulation of autophagy.
    Hou W; Han J; Lu C; Goldstein LA; Rabinowich H
    Autophagy; 2008 Oct; 4(7):940-3. PubMed ID: 18769107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of methyltransferases accelerates degradation of cFLIP and sensitizes B-cell lymphoma cells to TRAIL-induced apoptosis.
    Braun FK; Mathur R; Sehgal L; Wilkie-Grantham R; Chandra J; Berkova Z; Samaniego F
    PLoS One; 2015; 10(3):e0117994. PubMed ID: 25738497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Death receptor 5 is activated by fucosylation in colon cancer cells.
    Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
    FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Progress on targeting TRAIL's receptor as antitumor strategy].
    Chen SZ
    Yao Xue Xue Bao; 2009 Dec; 44(12):1336-42. PubMed ID: 21351465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Down-regulation of protein kinase Ceta potentiates the cytotoxic effects of exogenous tumor necrosis factor-related apoptosis-inducing ligand in PC-3 prostate cancer cells.
    Sonnemann J; Gekeler V; Sagrauske A; Müller C; Hofmann HP; Beck JF
    Mol Cancer Ther; 2004 Jul; 3(7):773-81. PubMed ID: 15252138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas.
    Sandra F; Hendarmin L; Nakamura S
    Oral Oncol; 2006 Apr; 42(4):415-20. PubMed ID: 16413220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.